Is CANF or TRAW more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat Traws Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Traws Pharma N/A -23,868.92% -165.52%

Do analysts recommend CANF or CURX?

Can-Fite BioPharma presently has a consensus target price of $44.00, suggesting a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Curanex Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Curanex Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CANF or CURX more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A Curanex Pharmaceuticals N/A -82.07% -79.65%

Do analysts prefer CANF or ENSC?

Can-Fite BioPharma presently has a consensus price target of $44.00, indicating a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Ensysce Biosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Ensysce Biosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend CANF or OBSV?

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is CANF or OBSV more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets Can-Fite BioPharma N/A N/A N/A ObsEva N/A -416.36% -92.01%

Do analysts recommend CNSP or CANF?

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than CNS Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Can-Fite BioPharma 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67

Is CNSP or CANF more profitable?

Can-Fite BioPharma's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -204.25% -141.87% Can-Fite BioPharma N/A N/A N/A

Can-Fite BioPharma (CANF) Competitors

$1.90 -0.10 (-5.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.89 -0.01 (-0.68%)

As of 10/9/2026 08:00 PM Eastern

Compare

CANF vs. TRAW, CURX, ENSC, OBSV, and CNSP

Should you buy Can-Fite BioPharma stock or one of its competitors? Can-Fite BioPharma's main competitors and comparable companies include Traws Pharma (TRAW), Curanex Pharmaceuticals (CURX), Ensysce Biosciences (ENSC), ObsEva (OBSV), and CNS Pharmaceuticals (CNSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Can-Fite BioPharma compare to Traws Pharma?

Can-Fite BioPharma (NYSE:CANF) and Traws Pharma (NASDAQ:TRAW) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Can-Fite BioPharma's return on equity of 0.00% beat Traws Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Traws Pharma	N/A	-23,868.92%	-165.52%

Traws Pharma has higher revenue and earnings than Can-Fite BioPharma. Traws Pharma is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.02	-$7.63M	-$14.80	N/A
Traws Pharma	$2.79M	2.45	$9.17M	-$1.74	N/A

In the previous week, Traws Pharma had 2 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Traws Pharma and 0 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Traws Pharma'saverage media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Traws Pharma	Neutral

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 2,215.79%. Traws Pharma has a consensus target price of $1.00, indicating a potential upside of 124.62%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts plainly believe Can-Fite BioPharma is more favorable than Traws Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Traws Pharma	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 8.0% of Traws Pharma shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 7.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Can-Fite BioPharma has a beta of 1.16, suggesting that its share price is 16% more volatile than the broader market. Comparatively, Traws Pharma has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Summary

Can-Fite BioPharma and Traws Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Curanex Pharmaceuticals?

Can-Fite BioPharma (NYSE:CANF) and Curanex Pharmaceuticals (NASDAQ:CURX) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations.

Curanex Pharmaceuticals has lower revenue, but higher earnings than Can-Fite BioPharma. Curanex Pharmaceuticals is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.02	-$7.63M	-$14.80	N/A
Curanex Pharmaceuticals	N/A	N/A	-$4.22M	-$7.80	N/A

Can-Fite BioPharma's return on equity of 0.00% beat Curanex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Curanex Pharmaceuticals	N/A	-82.07%	-79.65%

Can-Fite BioPharma has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Curanex Pharmaceuticals has a beta of -2.88, indicating that its share price is 388% less volatile than the broader market.

Can-Fite BioPharma presently has a consensus target price of $44.00, suggesting a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Curanex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Curanex Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

21.0% of Can-Fite BioPharma shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by company insiders. Comparatively, 39.7% of Curanex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Curanex Pharmaceuticals had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Curanex Pharmaceuticals and 0 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Curanex Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Curanex Pharmaceuticals	Neutral

Summary

Can-Fite BioPharma beats Curanex Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Can-Fite BioPharma compare to Ensysce Biosciences?

Can-Fite BioPharma (NYSE:CANF) and Ensysce Biosciences (NASDAQ:ENSC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

Can-Fite BioPharma has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -280.53%. Can-Fite BioPharma's return on equity of 0.00% beat Ensysce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
Ensysce Biosciences	-280.53%	-2,550.30%	-320.49%

21.0% of Can-Fite BioPharma shares are held by institutional investors. Comparatively, 5.6% of Ensysce Biosciences shares are held by institutional investors. 0.8% of Can-Fite BioPharma shares are held by insiders. Comparatively, 2.8% of Ensysce Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Ensysce Biosciences had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 1 mentions for Ensysce Biosciences and 0 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.00 equaled Ensysce Biosciences'average media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
Ensysce Biosciences	Neutral

Can-Fite BioPharma has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market. Comparatively, Ensysce Biosciences has a beta of 1, meaning that its share price has a similar volatility profile to the broader market.

Can-Fite BioPharma has higher revenue and earnings than Ensysce Biosciences. Ensysce Biosciences is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.02	-$7.63M	-$14.80	N/A
Ensysce Biosciences	N/A	N/A	-$10.18M	-$2.76	N/A

Can-Fite BioPharma presently has a consensus price target of $44.00, indicating a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher possible upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than Ensysce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
Ensysce Biosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Can-Fite BioPharma beats Ensysce Biosciences on 10 of the 14 factors compared between the two stocks.

How does Can-Fite BioPharma compare to ObsEva?

Can-Fite BioPharma (NYSE:CANF) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Can-Fite BioPharma presently has a consensus target price of $44.00, indicating a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Can-Fite BioPharma is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 17.5% of ObsEva shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by insiders. Comparatively, 14.4% of ObsEva shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Can-Fite BioPharma has higher revenue and earnings than ObsEva. Can-Fite BioPharma is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Can-Fite BioPharma	$405K	5.02	-$7.63M	-$14.80	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

Can-Fite BioPharma's return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Can-Fite BioPharma	N/A	N/A	N/A
ObsEva	N/A	-416.36%	-92.01%

In the previous week, Can-Fite BioPharma's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
Can-Fite BioPharma	Neutral
ObsEva	Neutral

Can-Fite BioPharma has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market.

Summary

Can-Fite BioPharma beats ObsEva on 9 of the 12 factors compared between the two stocks.

How does Can-Fite BioPharma compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Can-Fite BioPharma (NYSE:CANF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.0% of Can-Fite BioPharma shares are owned by institutional investors. 1.8% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 0.8% of Can-Fite BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 0 mentions for Can-Fite BioPharma. CNS Pharmaceuticals' average media sentiment score of 0.00 equaled Can-Fite BioPharma'saverage media sentiment score.

Company	Overall Sentiment
CNS Pharmaceuticals	Neutral
Can-Fite BioPharma	Neutral

CNS Pharmaceuticals has a beta of 3.1, meaning that its stock price is 210% more volatile than the broader market. Comparatively, Can-Fite BioPharma has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market.

Can-Fite BioPharma has a consensus target price of $44.00, suggesting a potential upside of 2,215.79%. Given Can-Fite BioPharma's stronger consensus rating and higher probable upside, analysts clearly believe Can-Fite BioPharma is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Can-Fite BioPharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Can-Fite BioPharma has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Can-Fite BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$23.59	N/A
Can-Fite BioPharma	$405K	5.02	-$7.63M	-$14.80	N/A

Can-Fite BioPharma's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-204.25%	-141.87%
Can-Fite BioPharma	N/A	N/A	N/A

Summary

Can-Fite BioPharma beats CNS Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

Get Can-Fite BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CANF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CANF vs. The Competition

Export

Metric	Can-Fite BioPharma	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$2.03M	$12.31B	$7.16B	$22.94B
Dividend Yield	N/A	2.64%	2.53%	3.72%
P/E Ratio	-1.06	797.58	275.02	28.60
Price / Sales	5.02	939.75	635.97	14.91
Price / Cash	N/A	85.97	76.38	37.72
Price / Book	1.08	10.71	11.22	4.72
Net Income	-$7.63M	$2.84B	$3.50B	$1.07B
7 Day Performance	-12.84%	-0.95%	-0.90%	0.35%
1 Month Performance	-12.04%	-4.93%	-4.43%	-2.94%
1 Year Performance	-82.11%	-4.13%	7.03%	9.25%

Can-Fite BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CANF Can-Fite BioPharma	1.5289 of 5 stars	$1.90 -5.0%	$44.00 +2,215.8%	-83.3%	$2.03M	$405K	N/A	5
TRAW Traws Pharma	1.5753 of 5 stars	$0.61 -1.9%	$1.00 +62.9%	-85.8%	$9.33M	N/A	N/A	7
CURX Curanex Pharmaceuticals	0.293 of 5 stars	$5.19 +4.4%	N/A	-64.1%	$8.15M	N/A	N/A	6
ENSC Ensysce Biosciences	1.1742 of 5 stars	$0.41 -0.7%	N/A	-77.4%	$8.06M	$5.07M	N/A	10	Positive News Gap Up
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:CANF) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Can-Fite BioPharma (CANF) Competitors

CANF vs. TRAW, CURX, ENSC, OBSV, and CNSP

How does Can-Fite BioPharma compare to Traws Pharma?

Summary

How does Can-Fite BioPharma compare to Curanex Pharmaceuticals?

Summary

How does Can-Fite BioPharma compare to Ensysce Biosciences?

Summary

How does Can-Fite BioPharma compare to ObsEva?

Summary

How does Can-Fite BioPharma compare to CNS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF vs. The Competition

Can-Fite BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Can-Fite BioPharma (CANF) Competitors

CANF vs. TRAW, CURX, ENSC, OBSV, and CNSP

How does Can-Fite BioPharma compare to Traws Pharma?

Is CANF or TRAW more profitable?

Which has better valuation and earnings, CANF or TRAW?

Does the media refer more to CANF or TRAW?

Do analysts rate CANF or TRAW?

Do insiders & institutionals believe in CANF or TRAW?

Which has more volatility and risk, CANF or TRAW?

Summary

How does Can-Fite BioPharma compare to Curanex Pharmaceuticals?

Which has better valuation and earnings, CANF or CURX?

Is CANF or CURX more profitable?

Which has more volatility & risk, CANF or CURX?

Do analysts recommend CANF or CURX?

Do institutionals and insiders hold more shares of CANF or CURX?

Does the media favor CANF or CURX?

Summary

How does Can-Fite BioPharma compare to Ensysce Biosciences?

Is CANF or ENSC more profitable?

Do institutionals & insiders believe in CANF or ENSC?

Does the media refer more to CANF or ENSC?

Which has more risk & volatility, CANF or ENSC?

Which has preferable earnings and valuation, CANF or ENSC?

Do analysts prefer CANF or ENSC?

Summary

How does Can-Fite BioPharma compare to ObsEva?

Do analysts recommend CANF or OBSV?

Do institutionals and insiders have more ownership in CANF or OBSV?

Which has stronger earnings & valuation, CANF or OBSV?

Is CANF or OBSV more profitable?

Does the media favor CANF or OBSV?

Which has more risk & volatility, CANF or OBSV?

Summary

How does Can-Fite BioPharma compare to CNS Pharmaceuticals?

Do insiders & institutionals hold more shares of CNSP or CANF?

Does the media prefer CNSP or CANF?

Which has more risk and volatility, CNSP or CANF?

Do analysts recommend CNSP or CANF?

Which has stronger valuation and earnings, CNSP or CANF?

Is CNSP or CANF more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CANF vs. The Competition

Can-Fite BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools